Skip to main content
Jinyu Bio-Technology Co.,Ltd. logo

Jinyu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 600201 ISIN · CNE000000Y37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,777 across all filing types
Latest filing 2021-04-22 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600201

About Jinyu Bio-Technology Co.,Ltd.

http://jinyubiotech.com/

Jinyu Bio-Technology Co., Ltd. focuses on the research, development, and manufacturing of veterinary biological products and pharmaceuticals. The company is a prominent supplier of animal vaccines, particularly specializing in Foot-and-Mouth Disease (FMD) vaccines, brucellosis vaccines, and solutions for swine and poultry diseases. It utilizes advanced biotechnology platforms, including large-scale suspension culture and high-efficiency purification processes, to produce high-titer, high-purity biologicals. The organization operates sophisticated research facilities and Biosafety Level 3 (P3) laboratories to support the development of diagnostic reagents and preventive treatments. Its operations center on enhancing animal health through scientific innovation, providing comprehensive disease control strategies for the global livestock industry and large-scale agricultural operations.

Recent filings

Filing Released Lang Actions
东北证券股份有限公司关于金宇生物技术股份有限公司2020年度募集资金存放与使用情况的核查意见
Regulatory Filings
2021-04-22 Chinese
金宇生物技术股份有限公司2020年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2020 年度内部控制评价报告' which translates to '2020 Annual Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2020, including financial reporting internal control and non-financial reporting internal control. The document contains detailed descriptions of internal control scope, standards, defect recognition, and remediation status. It is a comprehensive report on internal control evaluation rather than a brief announcement or certification. The content is substantive and specific to internal control evaluation, which aligns with an Audit Report / Information (AR) category, as it is a standalone audit-related report focusing on internal control evaluation and results, not a full annual report or other categories. The document length is 4131 characters, which is sufficient for a detailed report but not a full annual report. Therefore, the best classification is AR with high confidence. FY 2020
2021-04-22 Chinese
金宇生物技术股份有限公司2020年度独立董事述职报告
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Directors' Report" for the year 2020 by JinYu Biotechnology Co., Ltd. It details the independent directors' activities, attendance, oversight on governance, internal controls, related party transactions, and other compliance matters during the year. It is a narrative report on the independent directors' duties and observations rather than a financial report or announcement. It does not contain financial statements or earnings data, nor is it a notice or announcement of voting results or management changes. The content aligns with a governance-related report focusing on board and management oversight. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length (4574 characters) and detailed content support this classification with high confidence.
2021-04-22 Chinese
金宇生物技术股份有限公司2020年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the 2020 annual report summary of 金宇生物技术股份有限公司 (Jinyu Biological Technology Co., Ltd.). It contains detailed financial data for the year 2020, including total assets, revenue, net profit, and quarterly financial data. It also includes company business descriptions, accounting policy changes, shareholder information, and consolidated subsidiaries. The document is over 6,700 characters, which is substantial and contains actual financial statements and analysis. It is not merely an announcement or a certification. The content matches the characteristics of an Annual Report (10-K) as it covers comprehensive company activity and full financial performance for the fiscal year 2020. FY 2020
2021-04-22 Chinese
金宇生物技术股份有限公司2021年第一季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled '2021 年第一季度报告' which translates to '2021 First Quarter Report'. It contains detailed financial data such as total assets, net profit, cash flow, and shareholder information for the first quarter of 2021. The document includes financial statements and analysis of changes in financial indicators compared to the previous year. It explicitly states that it is an unaudited quarterly report. The presence of comprehensive financial data and analysis for a period shorter than a full fiscal year clearly identifies this as an Interim / Quarterly Report. The document length is over 5,000 characters and contains substantive financial data, so it is not merely an announcement or certification. Therefore, the correct classification is 'IR' (Interim / Quarterly Report). Q1 2021
2021-04-22 Chinese
金宇生物技术股份有限公司监事会关于回购注销2020年限制性股票激励计划部分限制性股票的核查意见
Regulatory Filings
2021-04-22 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.